4.5 Article

Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines

Journal

VACCINE
Volume 39, Issue 2, Pages 402-411

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2020.11.041

Keywords

Antibodies; Microneutralization test; Humoral immunity; Influenza A(H5N1); Pre-pandemic vaccine

Funding

  1. Finnish Institute for Health and Welfare (THL)
  2. Ministry of Social Affairs and Health (Finland)
  3. Identification of Mechanisms Correlating with Susceptibility for Avian Influenza (IMECS) project by the European Commission, DG Research [201169]

Ask authors/readers for more resources

The study found that sequential vaccination with two different H5N1 vaccines can induce long-lasting high level cross-subtype immunity, supporting a prime-boost vaccination strategy in vaccination plans.
Background: Avian influenza A(H5N1) viruses have caused sporadic infections in humans and thus they pose a significant global health threat. Among symptomatic patients the case fatality rate has been ca. 50%. H5N1 viruses exist in multiple clades and subclades and several candidate vaccines have been developed to prevent A(H5N1) infection as a principal measure for preventing the disease. Methods: Serum antibodies against various influenza A(H5N1) Glade viruses were measured in adults by ELISA-based microneutralization and haemagglutination inhibition tests before and after vaccination with two different A(H5N1) vaccines in 2009 and 2011. Results: Two doses of AS03-adjuvanted A/Indonesia/5/2005 vaccine induced good homologous but poor heterologous neutralizing antibody responses against different Glade viruses. However, non-adjuvanted A/Vietnam/1203/2004 booster vaccination in 2011 induced very strong and long-lasting homologous and heterologous antibody responses while homologous response remained weak in naive subjects. Conclusions: Sequential vaccination with two different A(H5N1) pre-pandemic vaccines induced long-lasting high level cross-Glade immunity against influenza A(H5N1) strains, thus supporting a prime-boost vaccination strategy in pandemic preparedness plans. (C) 2020 The Author(s). Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available